ArticleClinical and translational medicine2021

A CRISPR/CAS9-based strategy targets the personalized chimeric neosequence in fusion-driven cancer genome for precision medicine.

Wei Huang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.